An update in management of noncutaneous T-cell lymphomas.

about

Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.

P2860

Q38904928-2D258848-F3C9-4006-903F-D9B5ABBF2888

P2860

An update in management of noncutaneous T-cell lymphomas.

Item

http://www.wikidata.org/entity/Q41215812

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

An update in management of noncutaneous T-cell lymphomas.

@en

type

Item

label

An update in management of noncutaneous T-cell lymphomas.

@en

prefLabel

An update in management of noncutaneous T-cell lymphomas.

@en

P1476

An update in management of noncutaneous T-cell lymphomas.

@en

P2093

R H S Liang

http://www.w3.org/2001/XMLSchema#string

Y Y Hwang

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group

Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.

Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma.

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.

P304

424786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1155/2010/424786

http://www.w3.org/2001/XMLSchema#string

P478

2010

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49711733

http://www.w3.org/2001/XMLSchema#string

P698

21188274

http://www.w3.org/2001/XMLSchema#string

P932

3003949

http://www.w3.org/2001/XMLSchema#string

An update in management of noncutaneous T-cell lymphomas.

about

P2860

P2860

An update in management of noncutaneous T-cell lymphomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932